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Abstract—Ischemic mitral regurgitation is associated with
substantial risk of death. We sought to: (1) detail sig-
niﬁcant recent improvements to the Dassault Syste`mes
human cardiac function simulator (HCFS); (2) use the
HCFS to simulate normal cardiac function as well as
pathologic function in the setting of posterior left ven-
tricular (LV) papillary muscle infarction; and (3) debut our
novel device for correction of ischemic mitral regurgitation.
We synthesized two recent studies of human myocardial
mechanics. The ﬁrst study presented the robust and
integrative ﬁnite element HCFS. Its primary limitation
was its poor diastolic performance with an LV ejection
fraction below 20% caused by overly stiff ex vivo porcine
tissue parameters. The second study derived improved
diastolic myocardial material parameters using in vivo MRI
data from ﬁve normal human subjects. We combined these
models to simulate ischemic mitral regurgitation by com-
putationally infarcting an LV region including the poste-
rior papillary muscle. Contact between our novel device
and the mitral valve apparatus was simulated using
Dassault Syste`mes SIMULIA software. Incorporating im-
proved cardiac geometry and diastolic myocardial material
properties in the HCFS resulted in a realistic LV ejection
fraction of 55%. Simulating infarction of posterior papil-
lary muscle caused regurgitant mitral valve mechanics.
Implementation of our novel device corrected valve
dysfunction. Improvements in the current study to the
HCFS permit increasingly accurate study of myocardial
mechanics. The ﬁrst application of this simulator to
abnormal human cardiac function suggests that our novel
annuloplasty ring with a sub-valvular element will correct
ischemic mitral regurgitation.
Keywords—Finite element method, Realistic simulation,
Myocardial infarction, Ventricular function, Ischemic mitral
regurgitation, Mitral annuloplasty.
INTRODUCTION
Ischemic mitral regurgitation is a consequence of
adverse left ventricular (LV) remodeling after
myocardial injury, in which there is enlargement of the
LV chamber and mitral annulus, apical and lateral
migration of the papillary muscles, leaﬂet tethering,
and reduced coaptation area. These processes lead to
malcoapation of the leaﬂets and consequently mitral
insuﬃciency. The leaﬂets themselves are normal, and
the disease occurs in the myocardium rather than in
the valve itself.2 Despite this, beyond medical therapy,
surgical correction of mitral regurgitation has largely
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relied upon native valve repair or valve replacement. A
recent randomized clinical trial2 found no signiﬁcant
difference in LV reverse remodeling or survival at
12 months between patients who underwent mitral-
valve repair with ring annuloplasty and those who
underwent mitral-valve replacement. Replacement
provided a more durable correction however, with
mitral regurgitation recurring less than 1/10th as often
at 12 months compared to outcomes of valve repair.
We hypothesize that mitral-valve repair using a novel
annuloplasty ring with a sub-valvular element would
provide a more effective treatment of ischemic mitral
regurgitation than mitral-valve repair using a standard
annuloplasty ring. Our rationale is that the sub-
valvular element engages the chordae of the posterior
leaﬂet, and contacts the inferior free edge of said
leaﬂet. As a consequence, it counterbalances an apical
and lateral shifting of the coaptation line in patients
with ischemic cardiomyopathy, thus reestablishing
proper leaﬂet coaptation and valve function.
Computational modeling is one way to system-
atically assess the eﬀects of pathology and proposed
surgical repair on heart function.11 By simulating the
effect of disease or injury on the heart, simulations
allow investigators to explore a variety of pathologic
conditions that would be difﬁcult to consistently create
in vivo.6 Models also have an important role in cardiac
device design, as application of myriad treatment de-
signs to identical pathology allows for natural isolation
of treatment effects.8,18 However, current models of
cardiac function are limited by assumptions related to
geometry and material properties, and importantly,
none have been fully validated with detailed ex-
perimental data.17 Dassault Syste`mes SIMULIA re-
cently launched the Living Heart Project to develop an
integrated physics-based simulator of cardiac physiol-
ogy. The Living Heart model or Human Cardiac
Function Simulator (HCFS) not only includes the en-
tire heart—all four chambers, valves and major ves-
sels—but also includes the electrophysiology and
ﬁbrous architecture of the myocardium. There is in-
creasing evidence that this model can be used to predict
the progression of pathology and the outcome both of
surgical repair and use of cardiac devices. We recently
published a proof-of-concept methods paper using this
model to simulate the normal human heart.3 Although
groundbreaking, the initial model had some limita-
tions. Most importantly, the LV ejection fraction was
only 19%, much lower than the normal range at rest
(62.3 ± 6.1%) as assessed using radionuclide angio-
cardiography.14 In the current study, we simulated a
physiologically normal LV ejection fraction by using
more realistic heart geometry and diastolic myocardial
material properties than those proposed in the earlier
proof-of-concept paper.3
In this invited article concerned with mitral valve
function, pathology and therapeutic options, we
therefore seek to: (1) detail our signiﬁcant improve-
ments in the geometry and diastolic material properties
of the Dassault Syste`mes HCFS; (2) use the resulting
more realistic model to simulate normal cardiac func-
tion as well as abnormal cardiac function due to a
myocardial infarction that includes the posterior LV
papillary muscle; and (3) use the abnormal human
heart model to debut a novel annuloplasty ring with a
sub-valvular element for correction of ischemic mitral
regurgitation.
MATERIALS AND METHODS
Human Cardiac Function Simulator
We refer the interested reader to Sect. 2 of Bail-
largeon et al.3 for our continuum model of electro-
mechanical coupling based on the kinematic equations,
the balance equations, and the constitutive equations.
In Sect. 3 of that methods paper, we illustrate our
computational model, based on the strong and weak
forms of the governing equations, their temporal and
spatial discretizations, their linearizations, and the
handling of internal variables. In the present study, we
use a more realistic solid model of the human heart
(Fig. 1).
The Solid Zygote 3D Heart geometries for computer-
aided design (CAD) and simulation were created by
Zygote Media Group, Inc. (UT, USA). Generation I of
the Solid ZygoteHeart geometry (the one we used in Ref.
3) was developed using medical imaging data from a
single human subject in 2005. An 8-slice GE Light Speed
CT platform was used to acquire 5 mm axial slices, with
an imaging matrix of 512 9 512. Generation II of the
Solid ZygoteHeart geometry (the one used in the current
study) was created by the Zygote Media Group in 2013,
using improved imaging techniques. A 64-slice GE Light
Speed scanner, using retrospective ECG gating and
achieving a slice thickness of 0.75 mm with 512 9 512
imaging matrix, was used to acquire images of an
anonymous healthy middle-aged Caucasian male.
Imaging data was resampled to twice the voxel density in
each dimension, reformatted into standard cardiac
imaging views, and was manually segmented to create a
rough polygonal geometry. This rough geometry was
then cleaned of noise, artifacts, and anomalies using
standard 3D editing software (Symbolics/Nichiman
Graphics/Mirai, Wavefront, 3D Studio/3D Studio Max,
Alias Power Animator, Maya, Cinema 4D, Focus,
Amira, and SolidWorks). Just as for the ﬁrst generation
Solid Zygote 3D Heart, certain anatomic elements (e.g.,
papillary muscles, valves, and chordae tendineae) had to
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be added to the model manually, as their ﬁne detail could
not be captured well with clinical imaging technology. In
the same respect, the ﬁnest geometric details of certain
anatomical structures (e.g., trabeculae carneae) were
simpliﬁed so as to avoid an unnecessarily complex and
computationally demanding model. It is important to
note here that the Generation II Solid Zygote Heart ge-
ometry is a component of a larger anatomical collection
that includes integrated anatomical geometries of a 50th
percentile (U.S.) male and hence, there are no ‘‘patient-
speciﬁc’’ anatomical features of the heart model.
Figure 2 shows the electrical ﬁnite element model of
Zygote’s second-generation solid heart geometry dis-
cretized with 449,560 linear tetrahedral elements, 655
1D linear conduction elements, 103,770 nodes, and
103,770 electrical degrees of freedom. The model de-
picted in that ﬁgure was created using Abaqus CAE.
Figure 3 shows how the 655 1D linear electrical
conduction elements are distributed between the left
and right ventricles. Figure 4 shows the mechanical
ﬁnite element model of the human heart discretized
with 449,560 linear tetrahedral (C3D4) elements,
12,915 linear quadrilateral shells, 7577 linear triangular
(S4R reduced integration) shells, 636 linear truss
(T3D2) elements, 16,824 rigid triangular elements,
130,290 nodes, and 443,564 mechanical degrees of
freedom. The S4R is the only element type with
hourglass control (based on enhanced strain). Other-
wise, the muscle ﬁber model, the ﬂuid model, and most
of the model parameters in the current study are as
described in Sect. 4 of Baillargeon et al.3
The only non-valvular model parameters used in the
current study that diﬀer from those in Table 1 of
Baillargeon et al.3 relate to the passive material prop-
erties of myocardium, and are as follows:
k = 1000 kPa; a = 0.33 kPa; b = 7.08; aff = 0.25 kPa;
bff = 5.34; ass = 0; bss = 0; afs = 0; bfs = 0. Our ra-
tionale for modifying these parameters is to correct the
non-physiologic LV ejection fraction of the ﬁrst gen-
eration HCFS. In Baillargeon et al.3 we used model
parameter values from the literature (see references
listed in their Table 1) concerning electrical, me-
chanical, and electro-mechanical phenomena and ﬂow
in the heart, and modiﬁed unknown model parameter
values concerning circulation to simulate an LV pres-
sure–volume loop. The resulting LV pressures and
shape of the loop in Fig. 10 of that study are realistic,
but the LV volumes are not indicative of a normal
human heart. Speciﬁcally, end-diastolic and end-sys-
tolic volumes were 103 and 83 mL, respectively, cor-
responding to a stroke volume of 20 mL and an
ejection fraction of only 19.4% (=20 mL divided by
103 mL). In a recent study by Genet et al.8 ﬁve normal
human subject-speciﬁc LV models were created, with
an average ejection fraction of 56 ± 3.95%. In the
current study, the passive mechanical model parameter
values were obtained by ﬁtting the passive mechanical
behavior under shearing deformation obtained from
the constitutive model for the normal myocardium in
Appendix A of Genet et al.8 Figure 5 shows a com-
parison of passive mechanical behavior under shearing
deformation between the human heart model of Bail-
largeon et al.3 and the one used in the current study.
Since the current study was mainly concerned with
mitral valve function, pathology and therapeutic
options, additional attention was given to the me-
chanical properties of the leaﬂets and chordae. Fig-
ure 6 shows the ﬁt of model parameter values deﬁning
leaﬂet circumferential and radial stress–strain rela-
tionships to measurements from the study of May-
Newman and Yin.13 Thus, porcine data was used to
FIGURE 1. Solid model of the human heart used as the basis
for our improved model. It was created from computed to-
mography and magnetic resonance imaging; adapted with
permission from (Zygote Media Group and Inc., 2014).
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simulate human mitral tissue. Similarly, Fig. 7 shows
the ﬁt of model parameter values deﬁning chordae
basal and marginal stress–strain relationships to mea-
surements from the study of Kunzelman and
Cochran.10 In both cases, the Dassault Syste`mes SI-
MULIA optimization software Isight was used to
minimize least-squared differences between measured
and predicted stresses at matching strains.
Human Cardiac Function Simulator with LV
Myocardial Infarction
The state-of-the-art whole human heart model
described above was then modiﬁed in the most
FIGURE 2. Electrical finite element model of the human heart discretized with 449,560 linear tetrahedral elements, 655 1D linear
conduction elements, 103,770 nodes, and 103,770 electrical degrees of freedom. Red elements comprise the atria; blue elements
comprise the ventricles.
FIGURE 3. Representation of the 655 1D linear electrical
conduction elements in the LV (red) and RV (blue) used in the
HCFS.
FIGURE 4. Mechanical finite element model of the human
heart discretized with 449,560 linear tetrahedral elements,
12,915 linear quadrilateral shells, 7577 linear triangular shells,
636 linear truss elements, 16,824 rigid triangular elements,
130,290 nodes, and 443,564 mechanical degrees of freedom.
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straightforward manner to simulate regurgitant mitral
valve mechanics. This modiﬁcation involved creating
an LV region that included the posterior papillary
muscle. The myocardial material properties in that
region were modiﬁed to ensure that no active my-
ocardial stress was generated at any time during the
cardiac cycle, thus simulating infarction. Figure 8
shows the LV region in which active myocardial stress
development was suppressed.
Novel Device for Correction of Ischemic Mitral
Regurgitation
A recent randomized clinical trial2 conﬁrmed an
excess of incidence of recurrence of mitral regurgita-
tion at 1 year among patients undergoing mitral-valve
repair. The type of annuloplasty ring was based on the
surgeon’s preference. The protocol mandated the use
of an approved rigid or semi-rigid complete annulo-
plasty ring, which was downsized for the annulus
diameter. In collaboration with the Cleveland Clinic
(Ohio, USA) a prototype annuloplasty ring with a sub-
valvular element was developed (Fig. 9a). To the best
of our knowledge, it is the ﬁrst annuloplasty ring to
include a sub-valvular element. Our rationale is that
the sub-valvular element engages the chordae of the
posterior leaﬂet, and contacts the inferior free edge of
said leaﬂet. Consequently, it counterbalances an apical
and lateral shifting of the coaptation line in patients
with ischemic cardiomyopathy, thus reestablishing
proper leaﬂet coaptation and valve function. We cre-
ated a rigid ﬁnite element representation of this novel
device, which is shown in Fig. 9b. The device was
modeled as rigid for simplicity. Figure 10a is a close-up
view of the whole heart model with the left atrium
removed. Figure 10b clearly illustrates the computa-
tional geometry of our novel device in contact with the
mitral valve apparatus. Tight, frictionless contact
FIGURE 5. Comparison of passive mechanical behavior un-
der shearing deformation between the human heart model of
Baillargeon et al.3 and that used in the current study. ‘‘FN’’
stands for shear in the fiber-normal plane. ‘‘FS’’ stands for
shear in the fiber-sheet plane. True (Cauchy) stress and true
(logarithmic) strain are plotted in this figure.
FIGURE 6. Fit of leaflet stress–strain relationships (red indicates circumferential, blue indicates radial) to experimental data.
‘‘Exp’’ stands for experimental. True (Cauchy) stress and true (logarithmic) strain are plotted in this figure.
FIGURE 7. Fit of chordae stress–strain relationships to ex-
perimental data. Red line indicates basal chordae; blue line
indicates marginal chordae. ‘‘Exp’’ stands for experimental.
True (Cauchy) stress and true (logarithmic) strain are plotted
in this figure.
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between the device and the mitral valve annulus was
activated at numerous points that represented sutures.
It is important to point out here that there was
separation contact (separation was allowed); a stan-
dard penalty-based contact algorithm was used.
RESULTS
The more realistic geometry of the Generation II
Solid Human heart model, and improved diastolic
myocardial material properties caused LV ejection
fraction to increase from 19.4 to 55%. Figure 11 shows
normal LV behavior predicted by this model. Addi-
tionally, the model predicted maximum long-axis
shortening of 12.1 mm, which is in agreement with the
measurements (12.2 ± 3.8 mm) of Rogers et al.16
Figure 12 shows close-up views of the second gen-
eration HCFS with the left atrium removed to clearly
show the mitral valve in its open and closed states
during the cardiac cycle. Movie 1 shows the same view,
but with the mitral valve in action throughout the
cardiac cycle. To induce regurgitant mitral valve
mechanics, the size of the infarcted LV region was it-
eratively increased until the LV ejection fraction
decreased from 55 to 45%. The effect of myocardial
infarction on the LV pressure–volume loop is shown in
Fig. 13. Creating the infarcted LV region also resulted
in decreased mitral valve leaﬂet coaptation (Fig. 14).
This is shown dynamically in Movie 2. Simulation of
the annuloplasty ring with the sub-valvular component
resulted in an increase in mitral valve coaptation in the
area originally affected by the LV infarction. Figure 15
shows a close-up view of the model with the left atrium
removed to clearly illustrate this. Movie 3 shows the
same view but with the mitral valve in contact with our
novel device throughout the cardiac cycle. The
simulation was made with a rigid (ﬂat plane) annulo-
plasty ring and sub-valvular element, and thus, device
stresses and strains cannot be extracted from the ana-
lysis. In our opinion, another consequence of using
that particular rigid annuloplasty ring is that a non-
negligible regurgitant area characterized the post-
annuloplasty conﬁguration in the A1-P1 region in
FIGURE 8. Ischemic mitral regurgitation was simulated by preventing active myocardial stress to be developed in an LV region
(shown in red). Left: view of whole heart model; Right: close-up view of infarcted LV region showing endocardial surface and
posterior papillary muscle.
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Movie 3. On the other hand, we were able to extract
average forces (Fig. 16) in the chordae between the
posterior mitral valve leaﬂet and the posterior LV
papillary muscle during the cardiac cycle for the three
cases (i.e., healthy heart, heart with an LV myocardial
infarction, and diseased heart treated with our novel
device). After LV myocardial infarction, peak average
chordae force became 78% of that in the healthy heart.
Treatment of the diseased heart with our novel device
caused peak average chordae force to increase, to
116% of that in the healthy heart. Otherwise, average
chordae force in the treated case followed that in the
healthy case throughout the cardiac cycle.
DISCUSSION
Our study details three signiﬁcant advancements in
realistic simulation of human cardiac function, pa-
thology, and therapeutic options, for the entire heart.
First, incorporating improved cardiac geometry and
diastolic myocardial material properties in the Das-
sault Syste`mes human cardiac function simulator
(HCFS) caused LV ejection fraction to increase from
19% to a more physiological value of 55%. Second,
simulating infarction of the posterior LV papillary
muscle caused regurgitant mitral valve mechanics; a
pathologic state associated with a substantial risk of
death.2 Third, use of our undersized annuloplasty ring
that included a sub-valvular element corrected valve
dysfunction. Figure 10 clearly shows the impact of our
novel device; the engagement of the chordae causes the
posterior leaﬂet to move forward, which ultimately
causes improved coaptation of the valve leaﬂets during
ventricular systole. Moreover, our results suggest that
virtual valve repair, in combination with nonlinear
programming tools, e.g., the Dassault Syste`mes Aba-
qus software in conjunction with Isight, can be used to
optimize the design of novel devices for correction of
ischemic mitral or tricuspid regurgitation. Lastly, the
simulations could be repeated with a deformable an-
nuloplasty ring and sub-valvular element, and fatigue-
simulation software to make durability predictions.
The most eﬀective surgical approach for treating
severe ischemic mitral regurgitation remains contro-
versial.2 In the past few years, the use of mitral-valve
repair has greatly exceeded the use of replacement.7
However, no randomized trials have established the
superiority of repair across a spectrum of patients with
severe ischemic mitral regurgitation.2 In their corre-
spondence, Gorman et al.9 point out that there was
substantial reverse remodeling among the patients in
the repair group in Ref. 2 who did not have recurrent
moderate or severe mitral regurgitation. They propose
that all patients should undergo repair and that those
in whom postoperative moderate or severe mitral re-
gurgitation develops should undergo secondary per-
cutaneous mitral-valve replacement. According to
Acker et al.,1 a less speculative and less aggressive
approach would be to use predictive models of recur-
rent mitral regurgitation, and, in patients with a high
likelihood of recurrence, to use replacement or a more
complex repair technique that speciﬁcally addresses
leaﬂet tethering.
Ours is the second study to be performed as part of
the Living Heart Project. The ﬁrst,3 which presented a
proof-of-concept simulator for a four-chamber hu-
man-heart model created from computed tomography
and MRI data, illustrated the governing equations of
excitation–contraction coupling and discretized them
using an explicit ﬁnite element environment (Abaqus/
explicit).3 To illustrate the basic features of their
model, the authors visualized the electrical potential
and mechanical deformation across the human heart
throughout its cardiac cycle. Nine parameters deﬁned
FIGURE 9. Novel annuloplasty ring with a sub-valvular ele-
ment for correction of ischemic mitral regurgitation. a Pho-
tograph of actual prototype. b Finite element model of
prototype.
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the orthotropic passive myocardial response (as
measured in excised porcine myocardium by Dokos
et al.5), resulting in an LV ejection fraction of 19.4%.
In the present study, we used ﬁve different passive
mechanical parameter values to deﬁne transverse
isotropy with respect to the local myoﬁber direction
as observed in the LVs of ﬁve normal human sub-
jects, with a resultant ejection fraction of 55%. It
might seem quite surprising that these two sets of
model parameters (both supposedly representing
normal mammalian passive myocardial mechanical
properties) predict such different LV ejection frac-
tions. The most likely explanation for this discrep-
ancy is that the excised porcine myocardium studied
by Dokos and co-workers was abnormally stiff (in
contracture). This explanation seems to indicate that
material parameters determined or estimated from
in vivo clinical or experimental data predict cardiac
mechanics more realistically than those directly mea-
sured from ex vivo experimental data.
FIGURE 10. a Close-up view of whole heart model with left atrium removed. Sutures attaching the novel device to the mitral valve
annulus are shown in pink. b Side views showing finite element model of novel device in contact with mitral valve apparatus.
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FIGURE 11. Plots showing normal human heart behavior. a LV pressure–volume loop. b LV long-axis shortening vs. time.
FIGURE 12. Close-up views of whole heart model with left atrium removed to clearly show mitral valve in its open (left) and closed
(right) states during the cardiac cycle.
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Ours is one of the few ﬁnite element modeling
studies to include the mitral valve and the LV. The ﬁrst
ﬁnite element model of the LV with mitral valve19 did
not include the right ventricle or either atrium. In that
study, the authors expanded their previous ﬁnite ele-
ment models of the LV to incorporate the leaﬂets and
chordae of the mitral valve based on drawings of the
ex vivo ovine mitral apparatus. Their LV model was
based on MRI data from a sheep that developed
moderate ischemic mitral regurgitation after postero-
basal myocardial infarction. They demonstrated the
utility and power of their ﬁnite element model by using
it to test the hypothesis that a reduction in the stiffness
of the ischemic region will decrease dyskinesis of the
posterior LV wall, increase the displacement of the
posterior papillary muscle and thereby increase is-
chemic mitral regurgitation. However, in that study,
FIGURE 13. Effect of myocardial infarction (blue line) on LV
pressure–volume loop. The red line indicates no myocardial
infarction.
FIGURE 14. Effect of infarcted LV region on mitral valve leaflet coaptation. Left: view of entire mitral valve; Right: close-up view of
affected area.
FIGURE 15. Close-up view of the mitral valve in the whole
heart model with a simulated infarcted LV region. The left
atrium was removed to clearly show how the simulated novel
device increases mitral leaflet coaptation.
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the leaﬂets were not modeled to include contact, which
resulted in spurious penetration of the anterior leaﬂet
into the posterior leaﬂet. That limitation was corrected
in a subsequent study of the effect of annuloplasty ring
shape in ischemic mitral regurgitation.12,20 That study
concluded that the effects of saddle-shaped and
asymmetric mitral annuloplasty rings are similar. This
conclusion begs the question as to why are there so
many different mitral annuloplasty rings available to
cardiac surgeons and more importantly, on what basis
have they been designed.4,15
Study Limitations and Future Directions
In our study, we made signiﬁcant improvements in
cardiac geometry and diastolic myocardial material
properties in the Dassault Syste`mes HCFS. Opportu-
nity for added realism in the HCFS remains, however.
Our ultimate goal is to replace the compartment ap-
proach to the ﬂuids portion of the simulation with a
resolved 3D ﬂuid dynamics solution. A fully coupled
ﬂuid–structure interaction (FSI) model of the human
heart is highly desirable, albeit hugely challenging, and
the major focus of research for numerous investigators.
Kunzelman and co-workers6,11,17 are utilizing an ad-
vanced FSI model of the mitral valve system that
allows analysis of the valve in the normal, diseased, or
repaired states. Their ﬁndings are validated by utilizing
a well-established, but unique experimental, in vitro
system in which mitral valve function can be exten-
sively assessed. Once fully validated, their FSI model
can be used to explore and compare various types of
valvular pathology and repair. The long-term goal of
their research is to provide an advanced FSI model of
the mitral valve that could ultimately be used for in-
dividualized patient planning for mitral valve repair.
Including ﬂow analysis like that mentioned above
would allow us to predict shear stresses on the myocar-
dial wall, and more importantly, on the four heart
valves, through the entire cardiac cycle. Such an ap-
proach presents tremendous opportunities to better
understand the mechanisms of valvular disease and
optimize treatment in the form of valve repair or re-
placement, either through open heart surgery or
minimally invasive intervention. Despite the limited
treatment of ﬂuids in the current analysis, we are conﬁ-
dent that our novel annuloplasty ring with a sub-
valvular element will provide durable correction of is-
chemic mitral regurgitation because of (unpublished)
promising long-term outcomes data from treated sheep.
CONCLUSION
This study incorporated improved cardiac geometry
and diastolic myocardial material properties in the
Dassault Syste`mes HCFS, which resulted in a realistic
LV ejection fraction of 55%. Simulating infarction of
the posterior LV papillary muscle predicted regurgitant
mitral valve mechanics. Use of our undersized annulo-
plasty ring that included a sub-valvular element cor-
rected valve dysfunction. Our experience suggests that
valve repair can be further optimized with additional
software (e.g., fatigue, optimization) to develop novel
annuloplasty rings with sub-valvular elements for cor-
rection of ischemic mitral or tricuspid regurgitation.
FIGURE 16. Average forces in chordae between the posterior mitral valve leaflet and the posterior LV papillary muscle during the
cardiac cycle. The force time-courses were normalized by the peak average chordae force value in the healthy heart (red curve).
Also shown are the cases of LV myocardial infarction (blue curve) and diseased heart treated with our novel device (green curve).
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